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Abstract: Fluorescently labeled lectins are useful tools for in vivo and in vitro studies of the structure
and function of tissues and various pathogens such as viruses, bacteria, and fungi. For the evaluation
of high-mannose glycans present on various glycoproteins, a three-dimensional (3D) model of the
chimera was designed from the crystal structures of recombinant banana lectin (BanLec, Protein
Data Bank entry (PDB): 5EXG) and an enhanced green fluorescent protein (eGFP, PDB 4EUL) by
applying molecular modeling and molecular mechanics and expressed in Escherichia coli. BanLec-
eGFP, produced as a soluble cytosolic protein of about 42 kDa, revealed β-sheets (41%) as the
predominant secondary structures, with the emission peak maximum detected at 509 nm (excitation
wavelength 488 nm). More than 65% of the primary structure was confirmed by mass spectrometry.
Competitive BanLec-eGFP binding to high mannose glycans of the influenza vaccine (Vaxigrip®) was
shown in a fluorescence-linked lectin sorbent assay (FLLSA) with monosaccharides (mannose and
glucose) and wild type BanLec and H84T BanLec mutant. BanLec-eGFP exhibited binding to mannose
residues on different strains of Salmonella in flow cytometry, with especially pronounced binding
to a Salmonella Typhi clinical isolate. BanLec-eGFP can be a useful tool for screening high-mannose
glycosylation sites on different microorganisms.
Keywords: banana lectin; eGFP; fluorescence; viral glycoproteins; influenza vaccine; florescence-
linked lectin sorbent assay; Salmonella strains
1. Introduction
Lectins are carbohydrate-binding proteins involved in many biological processes like
recognition and binding of glycans, host-pathogen interactions, cell targeting, cell-cell
communication, induction of apoptosis, cancer metastasis, and differentiation [1,2]. Many
different lectins are known and their glycan-binding specificities characterized (consor-
tium for functional glycomics at http://www.functionalglycomics.org/). Antimicrobial
activities of lectins toward viruses, fungi, and bacteria have been reported [3], with plant
lectins as the well-characterized group.
The first report on the isolation of banana lectin (BanLec) was from Musa paradisiac [4].
It belongs to the jacalin-related superfamily (mJRL) of lectins, which recognizes and binds
to high mannose glycans [5]. It is homodimeric in solution, with a molecular mass of
about 26 kDa. Each subunit consists of twelve β-strands arranged in a β-Prism-I fold [6,7].
BanLec is an IgG4-inducing antigen [8] and a potent inhibitor of human immunodeficiency
virus (HIV) replication [9,10]. BanLec binds to the glycosylated proteins in the viral en-
velope and inhibits its cellular entry by blocking glycan-mediated interactions with the
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CD4 receptor and CCR5/CCR4 co-receptors on host cells [10]. Because of its ability to
induce T cell proliferation, BanLec has also been recognized as a potential immunomod-
ulatory molecule [11–13]. It was shown that mutation of the amino acid at position 84
from histidine to threonine minimizes the wild-type banana lectin’s mitogenicity, without
compromising antiviral activity against viruses that have high-mannose-type N-glycans
on their surfaces [14].
Fluorescently labeled lectins are useful tools for both in vivo and in vitro study of the
structure and function of tissues [15–17], pathological processes, including cancer [18–20],
as well as those initiated with pathogens such as viruses, bacteria, and fungi [21].
Lectins can be fluorescently labeled using a chemical approach. However, chemical
labeling can change the secondary and tertiary structure of lectins and consequently impair
their interaction with glycans [22]. The binding constant between lectins and glycans is
usually low, and every change of lectin structure can introduce a change of binding site
and potentially affect the binding constant.
Green fluorescent protein (GFP) is a ready-made fluorescent polypeptide that finds
broad application in various assays and in vivo imaging. The most explored application
is a genetic fusion with a protein of interest [23]. The fused protein preserves its function
along with the acquired fluorescent property of the GFP expressing gene. For instance,
a neurocan–GFP which specifically binds to hyaluronan was employed for revealing a
detailed picture of hyaluronan tissue distribution [24], while eGFP-Nictaba, the cytoplas-
mic/nuclear tobacco lectin, can interact with high-mannose and complex N-glycans [25].
Fluorescently labeled Aspergillus oryzae lectin is useful tool for the detection of the α(1,6)-
fucose attached to the core N-glycan (core fucose) of glycoproteins known to play essential
roles in various pathophysiological events [26].
In this study, we have designed in silico, produced, purified, and characterized
recombinant BanLec-eGFP chimera. The application of BanLec-eGFP was tested with
competitive florescence-linked lectin assay (FLLA) for studies of interactions between
the lectin and high-mannose carbohydrates present on the trivalent inactivated A and B
split-virion influenza vaccine; and with flow cytometry for the detection of high mannose
content lipopolysaccharides (LPS) on the surface of bacteria.
2. Materials and Methods
2.1. Strains and Plasmids
Escherichia coli strain DH5α (Invitrogen Thermo Fisher Scientific, Carlsbad, USA) was
used as a host to propagate plasmids pUC57-eGFP (GenScript HK Limited, Hong Kong,
China) and BanLec gene-containing pET-23b, pET-23b-BL. Bacteria were grown in Luria-
Bertani (LB) medium (10 g/L Tryptone (Torlak, Institute of Virology, Vaccines, and Sera,
Belgrade, Serbia), 5 g/L NaCl (Betahem, Belgrade, Serbia), 5 g/L yeast extract (Torlak), and
15 g/L agar (Torlak)) supplemented with antibiotics when appropriate.
2.2. Design, Cloning of eGFP in pET-23b-BL
The three-dimensional (3D) model of the BanLec-eGFP chimeric structure is designed
from the crystal structure of a recombinant banana lectin, Protein Data Bank (PDB) entry
5EXG [10] (chain A containing 141 amino acids) and the crystal structure of an enhanced
green fluorescent protein, PDB entry 4EUL [27] (chain A containing 239 amino acids)
by applying the molecular modeling and molecular mechanics to optimize the structure.
All modifications in the sequence of BanLec-eGFP chimera relative to the used crystal
structures, such as replacing the residues, removing the excessive, and adding the missing
residues, were done in Discovery Studio 19.1.0. [28] The N-terminal part (MVS) and C-
terminal fragment (GMDELYK) were modeled in a random coil conformation but ended
up with a few turns and bends.
A glycine-serine-glutamate-phenylalanine (GSEF) linker was constructed between
the BanLec and eGFP to prevent steric obstacles. The GSEF linker was modeled as a coil
extension to the β-strand secondary structure of the C-terminus of eGFP in Discovery
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Studio 19.1.0 [28]. The computer-generated BanLec-eGFP chimeric design was obtained
by connecting the three fragments and adding the hydrogen atoms, followed by the full
structural minimization in NAMD 2.9 [29] with CHARMM22 force field [30] in implicit
water model for 300 ps. The optimized resulting structure was strain-free, fully minimized,
and relaxed without any bond, angle, or torsion angle restraints, and van der Waals atomic
clashes. The final BanLec-eGFP structure comprised 384 amino acids, which encode for
the BanLec, linker GSEF, and enhanced green fluorescent protein (eGFP). The strategy of
cloning eGFP in the vector that already contains the BanLec gene sequence was conducted
using NdeI (Thermo Fisher Scientific, Waltham, MA, USA) and BamHI (Thermo Fisher
Scientific) restriction enzymes.
2.3. Expression of BanLec-eGFP
Escherichia coli BL21 (DE3)-pLysS (Agilent Technologies Inc., La Jolla, CA, USA) strain
was employed as host for the expression of recombinant chimera. Bacteria were grown
in LB medium containing 100 µg/mL of ampicillin and 25 µg/mL of chloramphenicol
until optical density (OD) at 600 nm of 0.6–0.8 was reached. The BanLec-eGFP synthesis
was induced by adding isopropyl-D-thiogalactopyranoside (IPTG) (VWR International,
LLC, Radnor, PA, USA) at a concentration of 1 mM, following incubation for 5 and 12 h
at 25 ◦C. After expression, the cell pellet obtained by centrifugation (3000× g for 20 min)
was resuspended in 150 mM NaCl, 20 mM tris(hydroxymethyl)aminomethane (TRIS) HCl
pH 7.6, and sonicated by the ultrasonic horn. The supernatant obtained by centrifugation
(3000× g for 20 min) was used for downstream processing of the expressed chimera.
2.4. Purification of Recombinant BanLec-eGFP
BanLec-eGFP was purified by combining affinity chromatography on branched α-
1,6 and α-1,3 glucan polymer (Sephadex G-75 superfine, column volume (CV) = 10 mL)
and ion-exchange chromatography (HiTrap ANX column, 1 mL, GE Healthcare, Little
Chalfont, UK). After pre-equilibration with 20 mM TRIS HCl pH 7.6, 150 mM NaCl (TRIS
buffered saline, TBS), the matrix (10 mL) was incubated with the protein solution at room
temperature for 1.5 h. After the transfer to a column and thorough washing with five
column volumes (CV) of TBS, bound BanLec-eGFP was eluted from the matrix with 0.3 M
glucose in TBS and collected in tubes (1.5 mL).
After affinity chromatography, collected samples were purified by ion-exchange chro-
matography connected to Äkta Purifier (GE Healthcare) using a combination of equilibra-
tion buffer (10 mM TRIS HCl, pH 8.0) and elution buffer (10 mM TRIS HCl, 0.5 M NaCl,
pH 8.0), at room temperature and a flow rate of 1 mL/min. The column pressure limit
was 0.3 MPa. Bound proteins were eluted using a linear gradient of elution buffer (0–100%
(v/v), for 10 column volumes). The BanLec-eGFP was eluted at 50% of the elution buffer.
The wild type BanLec (GenBank accession number EU0556441) and BanLec H84T
mutant were produced and purified according to the same protocol as BanLec-eGFP.
After purification, BanLec-eGFP protein was analyzed by Western blot. After blocking
the membrane with 5% skim milk in TBS with 0.05% Tween 20 (tTBS) for 1 h, polyclonal
rabbit anti-rBanLec antibodies [31] (dilution 1:10,000) were added, and the period of
incubation was 1 h. The membrane was washed, and alkaline phosphatase labeled goat
anti-rabbit IgG (Sigma-Aldrich, St. Louise, MO, USA) was added. The binding of labeled
antibodies for antigen was detected with nitro blue tetrazolium chloride/5-Bromo-4-chloro-
3-indolyl phosphate (Serva, Heidelberg, Germany).
2.5. Analysis of the BanLec-eGFP Structure by CD Spectroscopy, Fluorescent and
Mass Spectrometry
For assessing the secondary structures of the recombinant BanLec-eGFP, Circular
dichroism (CD) spectra were recorded at 25 ◦C on Jasco J-815 circular dichroism spectropo-
larimeter (JASCO Inc., Easton, PA, USA) in the wavelength range from 185 to 260 nm in a
cuvette with a path length of 0.1 mm. The CD data were collected in intervals of 0.1 nm, at a
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velocity of 50 nm/min. BanLec-eGFP was dialyzed against 20 mM TRIS HCl, pH 7.6 before
spectral analysis. Purified BanLec-eGFP (0.92 mg/mL, 80 µL) was used for the study.
The fluorescence of BanLec-eGFP was measured using a spectrofluorimeter FLUORO
MAX-4 Jobin Yvon (HORIBA, Kyoto, Japan). The emission spectra were recorded between
400–650 nm. The concentration of BanLec-eGFP used for the analysis was 0.92 mg/mL in
20 mM TRIS HCl buffer, pH 7.6.
To confirm the amino acid sequence, BanLec-eGFP was analyzed by mass spectrometry.
The protein sample was separated by SDS-PAGE, followed by Coomassie Blue staining
of the gel. The protein band corresponding to BanLec-eGFP was excised and destained
by 100 mM NH4HCO3/50% acetonitrile (ACN). The gel pieces were then reduced for
40 min by 20 mM dithiothreitol and subsequently alkylated with 50 mM iodoacetamide for
30 min in the dark. The samples were digested with sequencing grade trypsin according
to the manufacturer’s instructions (Promega, Mannheim, Germany). Before MS analysis,
samples were cleaned over the C18 zip tip (Millipore, MA, USA). For MS analyses of the
tryptic fragments, α-cyano-4-hydroxycinnamic acid as a matrix was used. Tryptic maps
were obtained on matrix assisted laser desorption ionization-time of flight/time of flight
(MALDI-TOF/TOF) Ultraflextreme mass spectrometer (Bruker) operating in a reflectron
positive mode and a peptide calibration standard mixture (Bruker 206195) was used for
mass calibration.
The obtained peptide masses were searched against the NCBI protein sequence
database using the MASCOT program (http://www.matrixscience.com/search_form_
select.html).
2.6. Competitive FLLSA (Fluorescence-Linked Lectin Sorbent Assay)
Recombinant BanLec-eGFP chimera was employed in competitive FLLSA for the
influenza virus detection to test its applicability in high-mannose binding assays. The assay
was performed by inhibiting the BanLec-eGFP binding to the immobilized hemagglutinin
from a Vaxigrip™ vaccine (Sanofi Pasteur, Lyon, France) with monosaccharides (mannose
or glucose), wild type BanLec, and BanLec H84T mutant. Black 96-Well Immuno plates
(Thermo Fisher Scientific) were coated with hemagglutinin (0.5 µg per well) in 15 mM
Na2CO3/35 mM NaHCO3, pH 9.5 overnight at 4 ◦C. Plates were washed with tPBS
(phosphate buffered saline, PBS with 0.05% Tween 20). Then, the plates were blocked with
3% bovine serum albumin (BSA) in tPBS for 1 h at 37 ◦C. After washing, BanLec-eGFP
(50 µg per well) was mixed without (control) or with different amounts of monosaccharides
(0.01, 0.1, 1, 10, 100, 1000, 5000 mM) or BanLec inhibitors (BanLec wt, or BanLec H84T; 0.01,
0.1, 1, and 10 µg per well), which were added to the wells, and incubated in the dark for
2 h at room temperature. The FLLSA was performed in triplicate and the emission was
measured at 535 nm on a fluorescent ELISA reader. Percent of inhibition was calculated as
% of inhibition = 100 ×
(




and IC50 value was determined as a concentration of inhibitor at 50% of inhibition.
2.7. Assessment of Fluorescence-Linked Lectin Binding to Bacterial Cells with Flow Cytometry
For the assessment of recombinant BanLec-eGFP binding to bacterial cells, 7 strains
of proteobacteria, species Salmonella enterica, subspecies enterica were used. The bacteria
used were: serovar Enteritidis ATCC 13076; serovar Enteritidis clinical isolate E; serovar
Typhimurium isolate B; serovar Typhimurium ATCC 14028; serovar Typhimurium isolate
2865; serovar Typhi clinical isolate 1243; and serovar Typhi clinical isolate 12. The bacteria
were cultivated in nutritious broth for 24 h and washed twice in PBS, by centrifugation
at 2000× g for 15 min. Cell density was adjusted to be the same for all strains, giving
optical density of 0.15 at 620 nm in a 100 µL volume in ELISA plate. The staining with
BanLec-eGFP was done by aliquoting the bacteria and adding BanLec-eGFP. Incubation
period was 15 min, at 4 ◦C, in the dark; followed by washing with PBS and centrifugation
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2000× g for 15 min two times. Finally, the bacteria were resuspended in PBS with 0.4%
formaldehyde (PBS-FA).
Inhibition with monosaccharides was performed on serovar Typhimurium isolate
2865. The bacterial suspensions were centrifuged for 15 min 2000× g and PBS was removed.
The bacteria were vortexed and different amounts of monosaccharides were added. This
was followed by the addition of 1 µg BanLec-eGFP. After incubation for 15 min, at 4 ◦C,
in the dark, the bacteria were washed twice by adding PBS, centrifuged as before, and
resuspended in PBS-FA. Each concentration point was done in quadruplicate.
The staining with BanLec-B (biotin labeled BanLec) was done the same way, except that
after washing the unbound BanLec-B 0.2 µg streptavidin-phycoerythrin (PE) (eBioscience)
was added and after 15 min of incubation, the bacteria were washed as before.
The signal was analyzed with FACSVerse with BD FACSuite software (BD Biosciences).
The graphs were drawn and results analyzed with OriginPro 8 and GraphPad Prism
software.
3. Results
3.1. Design, Cloning, Expression, and Purification of Recombinant BanLec-eGFP
The model of BanLec-eGFP chimera designed in silico and fully optimized with the
CHARMM22 force field [30] is depicted in Figure 1. Both carbohydrate-binding sites of
BanLec are highlighted, according to [32], for further analysis and discussion. The binding
site 1 consists of the GG loop (14–15), GKFLD loop (129–133) with additional S16 andV88
residues, while the binding site 2 includes the GG loop (59–60), GDVVD loop (34–38) with
additional T61 and F131 residues, which interact with the bound glycans stabilizing the
protein-receptor complex.
Enhanced green fluorescent protein (eGFP) is built up as the β-barrel tertiary structure
with the barrel’s fluorescent chromophore. The chromophore is generated by cyclization of
T66, Y67, and G68 backbone atoms, and its central position is shown in Figure 1A. On the
other hand, the β-strands with loops and turns define the tertiary structure of BanLec.
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eGFP) chimera is rendered as a solid ribbon. BanLec is shown in yellow, eGFP in green, glycine-
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Fig re 1. (A) The model structure of banana lectin-enhanced gree fluorescent protein (BanLec-
eGFP) chimera is rendered as a solid ribbon. BanLec is shown in yellow, eGFP in green, glycine-
serine-glutamate-phenylalanine (GSEF) linker in blue and carbohydrate-binding sites in pink. The
chromophore inside of eGFP is displayed as ball-and-stick. The depiction is made in Discovery
Studio 19.1.0 [28]. (B) SDS-PAGE represents the profile of expression and purification of BanLec-eGFP
(1—cell lysate before the addition of IPTG; 2—cell lysate after overnight expression; 3—BanLec-eGFP
after purification; 4—detection of BanLec-eGFP by the polyclonal rabbit anti-rBanLec antibodies;
MW, molecular weight marker). (C) Fluorescence spectra of BanLec-eGFP chimera. (D) Circular
dichroism (CD) spectra of BanLec-eGFP in the far-ultraviolet region (185–260 nm). (E) The amino acid
sequence of BanLec-eGFP chimera. The amino acid residues marked in red color represent the tryptic
peptides that have been experimentally confirmed by the MS analysis. The linker GSEF is marked in
blue. The theoretical pI = 5.66 and Mw = 41,925.32 Da for the BanLec-eGFP chimera. (F) The model
structure of the BanLec-eGFP construct was rendered in ribbon representation. The fragments of
the structure experimentally confirmed are shown in red, while the other parts of BanLec, linker,
and eGFP are displayed in yellow, blue, and green, respectively. The chromophore is shown in stick
rendering in a gray color. The depiction was made in Discovery Studio [28].
BanLec-eGFP chimera structure appears to be stable over the time of simulation,
mostly retaining the secondary and tertiary structure of both domains. The position of
eGFP should not affect the binding capacity of BanLec for the glycans.
Gene for eGFP was cloned in the pET-23b-BL vector, and the resulting protein was
expressed in E. coli BL21 (DE3)-pLysS. The addition of IPTG induced the expression of
BanLec-eGFP. The produced recombinant protein was purified by combining affinity
chromatography on a Sephadex G-75 superfine matrix and ion-exchange chromatography
on an ANX column. The BanLec-eGFP chimeric protein was confirmed with Western
blot using the polyclonal rabbit anti-rBanLec antibodies and alkaline phosphatase labeled
anti-rabbit IgG antibodies (Figure 1B).
The yield of BanLec-eGFP after purification was about 16 mg of protein per liter of
cell culture. The purified protein showed a band of approximately 42 kDa in SDS-PAGE
under reducing conditions. The theoretical molecular mass of BanLec-eGFP calculated by
the Compute pI/Mw tool (https://web.expasy.org/compute_pi/) was 41,925.32 Da.
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3.2. Physical-Chemical Characterization of BanLec-eGFP
Physical-chemical characterization of BanLec-eGFP chimeric protein was performed
by fluorescent spectroscopy, CD spectroscopy, and mass spectrometry. Fluorescent spec-
troscopy analysis revealed an emission maximum of BanLec-eGFP at 509 nm (Figure 1C).
Secondary structures of BanLec-eGFP were analyzed by CD spectroscopy in the far-UV
region from 185–260 nm (Figure 1D). The protein’s secondary structures were predicted by
the K2D program (http://cbdm-01.zdv.uni-mainz.de/~andrade/k2d2/), which revealed
the presence of 1.64% of α-helix and 40.58% of β-strand in the BanLec-eGFP. The spectra of
BanLec-eGFP showed well-defined secondary structures in the construct.
A peptide mass fingerprint was employed to confirm the primary structure of the
BanLec-eGFP. MS spectrometry data were compared with theoretically obtained data using
amino acid sequences (Source: https://web.expasy.org/peptide_cutter/). Peptides are
shown in Table 1.
Table 1. Theoretical and peptide masses of the tryptic fragments obtained by MS analysis. AA = amino acid. M = molecular
weight.
[M] Determined [M] Theoretical Peptide Sequence Peptide Length (-AA)
4474.01 4473.84 HNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSK 41
3914.708 3915.35 HFGGSGGTPHEIVLQEGEYLVGMAGEFGNYHGAVVLGK 38
2438.294 2437.73 GEELFTGVVPILVELDGDVNGHK 23
2082.038 2082.29 IFSGDVVDGVDVTFTYYGK 19
2023.074 2023.28 AYGPFGNTGGTPFSLPIAAGK 21
1973.927 1974.18 LEYNYNSHNVYIMADK 16
1542.819 1542.77 GIDFKEDGNILGHK 14
1503.769 1503.54 FSVSGEGEGDATYGK 15
1477.842 1477.75 AEVKFEGDTLVNR 13
1347.748 1347.64 TIFFKDDGNYK 11
1266.604 1266.39 SAMPEGYVQER 11
1050.576 1050.14 FEGDTLVNR 9
880.475 879.97 LGFSTNNK 8
821.416 820.90 QHDFFK 6
783.39 782.90 ISGFFGR 7
655.336 654.81 TIFFK 5
507.184 506.60 VNFK 4
430.225 430.50 NGIK 4
By mass analysis, more than 65% of the primary sequence was confirmed (Figure 1E).
While only one amino acid V88 belonging to the binding site 1 is experimentally verified,
all amino acid residues from the binding site 2 are confirmed by the MS analysis.
3.3. Competitive Inhibition of BanLec-eGFP Binding to Influenza Vaccine High-Mannose Glycans
BanLec-eGFP reactivity towards high-mannose glycans present on the influenza virus
vaccine was assessed by competitive FLLSA inhibition with monosaccharides mannose and
glucose, and wt BanLec and BanLec H84T. This assay was done with two controls, without
hemagglutinin (min) and inhibitor (max). The IC50 value for wt BanLec was 9.12 × 10−8 M,
while IC50 for BanLec H84T was 2.35 × 10−7 M, indicating 2.6 higher inhibition with wt
BanLec in the employed experimental settings. In accordance with our previous findings,
mannose was more efficient inhibitor for BanLec carbohydrate binding (Figure 2B) than
glucose [11].
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3.4. Flow Cytometric Detection of BanLec-eGFP binding to bacteria
The binding of BanLec-eGFP was detected to certain strains of Salmonella. As can be
seen in Figure 3, the binding was not uniform and showed differences between the strains,
with especially pronounced binding to serovar Typhi isolate 12 and serovar Typhimurium
isolate 2865, Figure 3 ,B. The binding was also detected to Salmonella enterica subsp. enterica
serovar Typhimurium ATCC 14028 and serovar Typhi isolate 1243, Figure 3C,D. Essentially
no binding was detected for the other strains tested, Figure 3E–G. The dependence of
relative fluorescence (FITC-A Median) on the concentration of BanLec-eGFP used to stain
different strains of Salmonella is shown in Figure 3H.
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The binding of BanLec-eGFP was completely dependent on lectin-carbohydrate
interaction as complete inhibition could be achieved with both mannose and glucose,
Figure 4A,B. Galactose could not inhibit this interaction even at a high concentration of
0.1 M. Inhibition with mannose gave IC50 ≤ 1.7 mM, which was substantially lower than
that obtained with glucose IC50 = 7.4 mM, Figure 4B.
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In order to compare the binding of BanLec-eGFP to Salmonella enterica serovar Ty-
phimurium isolate 2865 to that which would be obtained by using BanLec-B and streptavidin-
PE, a correlation was made, Figure 4C. A correlation coefficient of 0.875 was obtained
between the two staining procedures, with very little optimization, showing that the
correlation was highly significant (p = 0.0019).
4. Discussion
In this study, recombinant BanLec-eGFP chimera was in silico designed, produced,
and tested for application in the binding assay for high mannose structures present on
microorganisms.
The chimera retained the secondary structures of both individual proteins and the
structure was stable over the time of simulation, mostly retaining the secondary and tertiary
structures of both domains, and further on as demonstrated by functional assays. The
position of eGFP did not affect the binding capacity of BanLec for the glycans. This was
evaluated by testing the binding of BanLec-eGFP chimera to influenza virus antigens and
to different strains of Salmonella. These microorganisms were selected for analysis because
of the presence of mannose on their surface and because of the medical relevancy.
Viruses utilize envelope proteins for receptor recognition at the entry point into the
host cell. The antiviral activity of lectins is based on binding to oligosaccharides attached
to the viral envelope glycoproteins and inhibiting viral fusion and entry [33].
Many viruses such as HIV, severe acute respiratory syndrome corona viruses (SARS-
CoV, SARS-CoV-2), herpes simplex virus (HSV), Ebola, hepatitis B virus (HBV), hepatitis C
virus (HCV), influenza, West Nile virus, dengue virus, and zika virus have glycosylated
envelope proteins [33,34]. The importance of protein-sugar interactions is best illustrated
by the fact that the currently used therapeutics against influenza, Tamiflu (Oseltamivir)
and Relenza (Zanamivir), function as sialic acid analogs [35].
Antiviral lectins interact with glycan structures added as post-translational modifi-
cations to the viral envelope proteins [34,36]. The anti-HIV activity has been reported for
the mannose-binding lectins such as the lectin from banana (BanLec), microvirin from the
cyanobacterium Microcystis aeruginosa, scytovirin from the cyanobacteria Scytonema varium,
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lectin from snowdrop (GNA), and lectin from the red alga Griffithsia sp. (Griffithsin—
GRFT). They have been proposed as antiviral microbicides in the prevention of HIV
transmission [36,37]. Anti-influenza activity has been shown for some lectins, such as
BanLec [38], cyanovirin-N [39], NICTABA (Nicotiana tabacum agglutinin), and UDA (Urtica
dioica agglutinin) [40].
Various lectins have been fuzzed with fluorescent proteins as fluorescent probes for the
detection of specific glycan structures present on the cell-surface or intracellular conjugates,
making them versatile primary detection reagents. The neurocan–GFP was successfully
employed for the detection of hyaluronan tissue distribution [24]. Fluorescently labeled
Aspergillus oryzae lectin was a useful probe for the detection of the core fucose in N- glycans,
but can be also useful vehicles for delivery of substances into the cells [26].
Vaxigrip®, Sanofi Pasteur IIV3, used in this study is a trivalent vaccine, containing
antigens from A/H1N1, A/H3N2, and B strains, inactivated A and B split-virion influenza
vaccine, (15 µg of haemagglutinin for each strain) [41]. By employing BanLec-eGFP in the
competitive FLLSA, it was shown that wt BanLec exhibits higher binding for high mannose
glycans present on the employed influenza vaccine than the H84T BanLec mutant, contrary
to some literature data [14,38].
In order to assess the binding potential of BanLec-eGFP to highly mannosylated
microorganisms, based on our experimental data and literature data, we decided to use
Sallmonella. Previously we demonstrated that selectivity of rBanLec to fungal β-glucans
can be achieved in enzyme linked lectin sorbent assay (ELLSA) [42]. The ability of BanLec
to bind fungal β-glucans has been demonstrated previously by Goldstein et al. [43]. On
that occasion [42] Salmonella was not included in the analysis. After conducting ELLSA to
test the binding of BanLec to Salmonella, we detected approximately equal binding to that
obtained with yeast cells.
Salmonella is a well-known bacterial pathogen that causes both food-borne gastroenteri-
tis in humans and animals and typhoid fever. There are currently two species of Salmonella,
with Salmonella enterica being medically relevant. Within the species of S. enterica individual
subspecies and serovars have been identified. Different serovars are differentiated by the
structures of their flagellum, carbohydrates, and lipopolysaccharides (LPS) [44,45]. Certain
strains of Salmonella are known to contain mannose-rich LPS, and the binding of Mannose-
binding lectin (MBL) to this LPS has been investigated [46–48]. Studies on the effect of MBL
binding to S. enterica serovar Typhimurium have revealed the bactericidal properties of
MBL [39,40]. The inhibitory effect of MBL on the motility of Salmonella occurs by affecting
the energy source required for motility and the signaling pathway of chemotaxis [48].
The binding of MBL to a strain of Salmonella producing a mannose-rich LPS was
previously demonstrated with the similar principle employed in this study, by the binding
of fluorochrome conjugated anti-MBL serum [46]. The approach used in this study is a
direct one, with the novel BanLec-eGFP chimera, and the results indicate that BanLec-eGFP
acts in a similar fashion as MBL, which remains to be corroborated by parallel testing.
Important to note is that we have obtained differences between individual serovars
and strains. In particular, serovar Typhi clinical isolate 12, showed highest binding. The
tested strains from serovar Enteritidis showed no binding, while variations between strains
in the serovar Typhimurium have been noticed. MBL does not bind to nonpathogenic mu-
tants of Salmonella enterica serovar Montevideo that lack the mannose-rich O-polysaccharide
within LPS [46] leading to the question whether mannosylation influences the pathogenic-
ity of these organisms and in what way. The novel BanLec-eGFP chimera represents an
excellent novel tool for such analysis.
In this study, we have demonstrated by inhibition experiments with monosaccharides
that the binding of BanLec-eGFP to microorganisms occurs through the interaction of the
lectin with the saccharide component. Moreover, we have demonstrated that there is no
significant influence of the addition of GFP to the specificity of BanLec.
Each lectin molecule is characterized by affinity, specificity, and selectivity, and the
comparison of different lectins can be done within basic research studies. We previously
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compared BanLec with other mannose binding lectins such as Concanavalin A and Lens
culinaris agglutinin (LCA) and found profound differences [42]. In biotechnology, often
relying on the knowledge obtained through basic research, a more targeted approach, with
a specific purpose should always be applied. Based on the results presented above and
other literature data, further studies including the comparison of MBL with BanLec should
be performed.
In conclusion, BanLec-eGFP was produced in high yield, with retained secondary
structures in both domains. The protein is stable and offers the advantage of constant
emission capacity, unlike the chemically labeled lectin molecules, which increases repro-
ducibility.
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